Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 seralutinib inhalation study in pulmonary hypertension associated with interstitial lung disease
MOH_2025-10-20_014383Phase 3Completed
- Sponsor
- GB002, Inc.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of seralutinib in pulmonary hypertension associated with interstitial lung disease (PH-ILD) (3 arms), sponsored by GB002, Inc. Primary endpoints: Change in 6-minute walk distance at Week 24 and Long-term safety and tolerability in the extension phase. Started Sep 2025; status: completed.
02
Drugs
seralutinib
03
Conditions
pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Beyond the preview
Go deeper on MOH_2025-10-20_014383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-20_014383.